HRTIS.HE

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10000	+0.0%	$-0.16	$-0.16–$-0.16	—	1
2027	$10000	+0.0%	$-0.18	$-0.18–$-0.18	—	1
2028	$10000	+0.0%	$-0.24	$-0.24–$-0.24	—	1
2029	$10000	+0.0%	$-0.23	$-0.23–$-0.23	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 3 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-20	$-0.06	$-0.09	-50.0%
2025-03-31	$-0.11	$-0.11	-1.6%
2024-08-22	$-0.14	$-0.13	+4.8%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
HRTIS.HEHerantis Pharma Oyj	$1.41	-1.40%	$37M	—
BIOBV.HEBiohit Oyj	$2.38	-0.42%	$36M	—
MODU.HEModulight Oyj	$1.14	+12.32%	$48M	—
NANOFH.HENanoform Finland Oyj	$0.86	+1.17%	$74M	—
NXTMH.HENexstim Plc	$9.70	-0.51%

Herantis Pharma Oyj

Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.

www.herantis.com

Employees: 14
IPO / List date: Jun 11, 2014
HQ: FI

Held by traders on TradeandTell

No one on the platform currently holds HRTIS.HE.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in HRTIS.HE as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded HRTIS.HE yet.